Biodegradable Tumor Depot for Sustained Local Immunomodulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods, such as systemic injections and direct tumor injections, lead to non-specific systemic inflammatory responses and require frequent administration, necessitating the development of sustained formulations for immunomodulators.
Innovation Solution
The use of nano-bio formulations comprising biodegradable polymers and STING agonists or PARP inhibitors, which are implanted at a tumor site for sustained release over periods ranging from hours to days, allowing for continuous immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic intravenous injections of immunomodulators are used, then immune activation is achieved, but non-specific systemic inflammatory responses occur
Solution Approach 1:
The patent applies local quality by formulating immunomodulators in nano-bio formulations that target specific tumor sites. The formulations are designed to release immunomodulators locally at the tumor site rather than systemically, achieving immune activation while minimizing non-specific systemic inflammatory responses through localized delivery mechanisms.
Solution Approach 2:
The patent uses nano-bio formulations as intermediaries between the immunomodulators and the tumor site. These formulations act as carriers that protect the immunomodulators from systemic degradation and facilitate targeted delivery to the tumor, thereby achieving reliable immune activation without widespread systemic inflammation.
2Object-affected harmful factors
If direct tumor site injections are used, then localized treatment is achieved, but frequent weekly administration is required
Solution Approach 1:
The patent implements continuity of useful action by designing nano-bio formulations that provide sustained release of immunomodulators over extended periods. The formulations maintain continuous therapeutic activity at the tumor site for weeks or months, eliminating the need for frequent weekly injections and reducing overall treatment time loss.
Solution Approach 2:
The patent applies preliminary action by pre-formulating immunomodulators in nano-bio formulations that are designed for sustained release. This preliminary formulation allows the drug to be prepared in advance with controlled release characteristics, enabling long-duration treatment without requiring repeated administration visits.
3Reliability
If frequent weekly injections are administered, then immune system activation is maintained, but patient clinic visits increase
Solution Approach 1:
The patent uses continuity of useful action by creating nano-bio formulations that maintain immune system activation over extended periods. The sustained release mechanism ensures continuous therapeutic effect without requiring frequent clinic visits, thereby improving patient productivity while maintaining reliable immune activation.
Solution Approach 2:
The patent applies self-service by designing formulations that automatically release immunomodulators over time without requiring external intervention. The formulation itself maintains the therapeutic effect through its controlled release mechanism, eliminating the need for frequent patient visits to administer additional doses.
4Productivity
If high concentration immunomodulators are used, then treatment efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The patent applies local quality by concentrating immunomodulators within nano-bio formulations that target specific tumor sites. This localized concentration achieves high treatment efficacy at the tumor site while avoiding systemic toxicity, as the formulations are designed to release the immunomodulators locally rather than distributing them systemically.
Solution Approach 2:
The patent uses nano-bio formulations as intermediaries that protect the immunomodulators from systemic circulation. The formulation acts as a controlled release mechanism that maintains high local concentration for efficacy while preventing systemic absorption, thereby achieving treatment efficacy without proportional increases in systemic toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces the frequency of patient visits by providing prolonged immunomodulation, directing treatment to the tumor site, and minimizing systemic toxicity, thereby enhancing immune activation and treatment efficacy.
Implementation Method 1
a depot comprising a biodegradable polymer and a STING agonist or a PARP inhibitor (PARPi)... the depot releases the STING agonist or the PARPi at the tumor site for a period of time
Implementation Method 2
the STING agonist or the PARPi is distributed in the biodegradable polymer... releases the STING agonist or the PARPi at the tumor site
Data Source
AI summary
Disclosed are sustained biodegradable implant (a depot) that releases high drug doses directly into the tumor for treating cancer. The depot comprises a biodegradable polymer and a STING agonist and/or a PARP inhibitor (PARPi); wherein the STING agonist or the PARPi is distributed in the biodegradable polymer. The depot activates anticancer innate and adaptive immunity within the tumor microenvironment and promote immune infiltration of secondary, metastatic sites.